Display options
Cite
Zhang H, Zhang P, Zhang Y, et al. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. Postepy Kardiol Interwencyjnej. 2016;12(3):247-53doi: 10.5114/aic.2016.61647.
Zhang, H., Zhang, P., Zhang, Y., Yan, J., Dong, P., Wang, Y., & Niu, X. (2016). Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 12(3), 247-53. https://doi.org/10.5114/aic.2016.61647
Zhang, Hengliang, et al. "Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis." Postepy w kardiologii interwencyjnej = Advances in interventional cardiology vol. 12,3 (2016): 247-53. doi: https://doi.org/10.5114/aic.2016.61647
Zhang H, Zhang P, Zhang Y, Yan J, Dong P, Wang Y, Niu X. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. Postepy Kardiol Interwencyjnej. 2016;12(3):247-53. doi: 10.5114/aic.2016.61647. Epub 2016 Aug 19. PMID: 27625688; PMCID: PMC5011541.
Copy Download .nbib Format: NLM
Share it on

Postepy Kardiol Interwencyjnej. 2016;12(3):247-53. doi: 10.5114/aic.2016.61647. Epub 2016 Aug 19.

Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Hengliang Zhang, Pei Zhang, Yaheng Zhang, Junqiang Yan, Pingshuan Dong, Yanyu Wang, Xiaowei Niu

Affiliations

  1. Department of Cardiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  2. The First College of Clinical Medical, Lanzhou University, Lanzhou, China.

PMID: 27625688 PMCID: PMC5011541 DOI: 10.5114/aic.2016.61647

Abstract

INTRODUCTION: Heart failure (HF) is always complicated with anemia and is associated with bad prognosis in this patient population. Several studies have assessed the potential role of erythropoietin-stimulating agent (ESA) in improving cardiac function and reducing the number of hospitalizations in anemic patients with HF.

AIM: We performed a meta-analysis to assess the potential role of ESA in the treatment of anemic patients with HF.

MATERIAL AND METHODS: A literature and Medline search was performed to identify studies with control groups that examined the efficacy of ESA therapy in patients with HF and anemia.

RESULTS: A total of 11 studies were included (n = 3044 subjects) in the final analysis. Compared to placebo, ESA therapy was associated with increased hemoglobin levels (1.89 g/dl; 95% CI: 1.64-2.14, p < 0.00001), increased left ventricular ejection fraction (LVEF) to 6.88 (95% CI: 0.49-13.28, p = 0.03), decreased B-type natriuretic protein (-272.20; 95% CI: (-444.52)-(-99.89), p = 0.002), improvement in New York Heart Association functional class to -0.33 mean difference (95% CI: (-0.44)-(-0.23), p < 0.00001), and decreased hospitalization (OR = 0.61, 95% CI: 0.39-0.94, p = 0.02). There was no significant between-group difference in all-cause mortality (OR = 0.78, 95% CI: 0.51-1.21, p = 0.27).

CONCLUSIONS: The treatment of anemia with ESA therapy did not reduce the rate of all-cause mortality among patients with heart failure, but ESA therapy made a potential important contribution to patients' symptomatic improvement.

Keywords: anemia; erythropoietin-stimulating agents; heart failure; meta-analysis; randomized controlled trials

References

  1. J Am Coll Cardiol. 2002 Jun 5;39(11):1780-6 - PubMed
  2. Value Health. 2008 Jan-Feb;11(1):57-75 - PubMed
  3. Circulation. 2003 Jan 21;107(2):294-9 - PubMed
  4. Circulation. 2008 Jan 29;117(4):526-35 - PubMed
  5. N Engl J Med. 2013 Mar 28;368(13):1210-9 - PubMed
  6. Am Heart J. 2009 Dec;158(6):965-71 - PubMed
  7. N Engl J Med. 2009 Nov 19;361(21):2019-32 - PubMed
  8. Eur Heart J. 2007 Sep;28(18):2208-16 - PubMed
  9. Heart Fail Clin. 2014 Apr;10(2):281-94 - PubMed
  10. Am Heart J. 2008 Apr;155(4):751.e1-7 - PubMed
  11. Eur Heart J. 2008 Jun;29(12):1510-5 - PubMed
  12. Congest Heart Fail. 2007 Sep-Oct;13(5):289-92 - PubMed
  13. Am Heart J. 2005 Mar;149(3):391-401 - PubMed
  14. Future Cardiol. 2013 May;9(3):437-44 - PubMed
  15. J Am Coll Cardiol. 2005 Jul 5;46(1):125-33 - PubMed
  16. Am Heart J. 2006 Dec;152(6):1096.e9-15 - PubMed
  17. J Am Coll Cardiol. 2007 Feb 20;49(7):753-62 - PubMed
  18. Am J Med. 2005 May;118(5):496-502 - PubMed
  19. J Am Coll Cardiol. 2008 Sep 2;52(10):818-27 - PubMed
  20. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4802-6 - PubMed
  21. N Engl J Med. 2010 Jan 21;362(3):189-92 - PubMed
  22. Blood. 2006 Mar 1;107(5):1747-50 - PubMed
  23. Lancet. 2007 Feb 3;369(9559):381-8 - PubMed
  24. J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80 - PubMed
  25. Curr Opin Cardiol. 2009 Mar;24(2):172-8 - PubMed
  26. J Cardiovasc Pharmacol. 2005 Aug;46(2):155-61 - PubMed
  27. Am J Cardiol. 2003 Apr 1;91(7):888-91 - PubMed
  28. Eur Heart J. 2005 Nov;26(21):2232-7 - PubMed
  29. Am Heart J. 2007 Oct;154(4):645.e9-15 - PubMed
  30. Heart Fail Clin. 2010 Jul;6(3):359-72 - PubMed
  31. Circulation. 2010 Jan 19;121(2):245-51 - PubMed
  32. Eur J Cardiovasc Prev Rehabil. 2008 Jun;15(3):365-9 - PubMed

Publication Types